The most complex organ in the body requires a comprehensive approach to restore wellness.
A typical adult has over 100 billion brain cells, each with an average of 1000 synaptic connections. Every thought, action, and emotion you feel involves complex interactions between your brain cells which involve neuro transmitters. These are chemicals that help your brain cells communicate. Most mental disorders involve an imbalance or some form of dysfunction at these communication points and an alteration of these key brain chemicals.
The Role of Neurotransmitters in Mental Health
What is often not fully appreciated is that the neurotransmitters are made in the body. There are over 100 neurotransmitters now identified, though most research has focused on a few key ones. Serotonin is produced from the amino acid tryptophan (found in protein) and the final reaction requires vitamin B6 (The process also requires tryptophan hydroxylase 2, which is transcriptionally activated by vitamin D). Dopamine can be made from either of 2 amino acids and requires iron and folate. Norepinephrine is made from dopamine and requires adequate copper. GABA requires adequate zinc and B6 for its synthesis and regulation. Good mental health requires proper neurotransmitter activity at the synapses. This means you need a healthy synapse as well as adequate levels of the neurotransmitters.
Many medications target these key neurotransmitters by impacting the “reuptake” of them at the synapse, such as SSRIs – Serotonin Reuptake Inhibitor antidepressants. The synapse is the gap between 2 neurons where the electrical signal is turned into a chemical signal that moves across the space. The “reuptake” is where the neurotransmitter chemicals are whisked from the synapse like a vacuum inhaling dust, which returns the brain cell to its original state. This process is performed by transporters that are embedded in the cell membranes, creating a form of passageway. The rate of production of these transporters can change, and is regulated by “epigenetic” expression of genes.
Epigenetics is the means through which our genes are activated or deactivated thereby changing metabolic pathways and altering the risk of developing a disease. Epigenetics explains why one identical twin can develop a disease whilst the other does not.
The methylation (adding a CH3 chemical group) of DNA can switch off genes that produce neurotransmitter proteins. This causes the person to have reduced serotonin activity and a tendency towards depression. The reverse process, over methylation could cause excessive dopamine and a tendency towards anxiety. Multiple researchers  have found “over methylators” tended to have distinct character traits compared to “under methylators” and the different groups required different treatments to get better. They also found urinary pyrrole excretion (a marker of oxidative stress) was higher in people with mental illness than those without, and this correlated with a certain pattern of character traits. (Read common symptoms of Undermethylators here and Overmethylators here).
A person’s metabolism and nutritional status can and does impact their mental health. The main mechanism through which this occurs is epigenetics.
Countless environmental influences can cause these epigenetic changes, such as nutritional deficiencies or excesses, toxin exposures or stress. It makes sense then if we could optimise nutrition and neurotransmitter production, we could bring about new epigenetic changes and improve mental health.
This is the basis of the Pfeiffer-Walsh protocol (BioBalance)
in which we have been trained.
Dr.Walsh has had clinical experience with a massive number of patients and has analysed their biochemistry. He has worked with 10,000 patients with behaviour and ADHD issues, 3,500 people with Schizophrenia, 3,200 people with depression, and 1,500 Bipolar disorder patients.
Researchers such as Abram Hoffer, Dr.Walsh, Dr.Stuckey, Brett Lambert, Carl Pfeiffer and Dr.Mensah  have shown repeatedly that success is possible in treating mental illnesses using personalised high doses of selected nutritional supplements as they bring about epigenetic changes.
Certain nutrients in the right concentration for the right person can be powerful. Recent research agrees.
In a 12 month Australian study, 567 patients with a range of serious conditions (Autism Spectrum, ADHD, Asperger’s Syndrome, Anxiety, Bipolar Disorder, Depression, Schizophrenia and Obsessive Compulsive Disorder), were treated with a personalised nutritional therapy. It resulted in 64% having improvement (45% had major improvement, 19% partial improvement, and 14% nil improvement).
The study used 3 nominated quality of life outcomes to measure these improvements though hospital admission was substantially lower in the treatment group as well, and 22% were able to reduce their prescription medication. In the comparison group not receiving the equivalent nutrient treatment 19% had a major improvement, 19% partial improvement, and 62% noted nil improvement.
The study highlighted that most patients with the best results used a combination of both pharmacological and nutritional interventions. Over time the amount of medication is often reduced, but this is only after the nutrient therapy has had time to work.
A 2018 paper  found people who suffer from mood and anxiety problems may benefit from improved nutritional status achieved with targeted nutritional supplements. Their year-long trial had 16,020 participants and found 49.2% (n = 7878) who reported any level of depression or anxiety at baseline improved at follow-up. Of those who reported severe/extreme depression at baseline (n = 829), 97.2% reported improvement after one year. Regression analyses revealed a significant association of improvement in depression and anxiety with higher vitamin D status (>100 nmol/L) and more strenuous physical activity.
Another recent study  examining depression in mice demonstrated that 6 weeks of a Magnesium deficient diet induced depressive symptoms in mice, which was associated with changes in gut microbiota and neuroinflammatory marker hippocampal IL-6.
You Need Our Precision Approach
As Dr.Walsh says: “After clinical experience with thousands of mental health patients, I was surprised to learn that nutrient overloads usually cause more mischief than deficiencies. This explains why most multivitamin/mineral products are ineffective for mentally ill patients and can cause more harm than good. Patients with an overload of copper, methionine, folic acid or iron are likely to deteriorate if they take supplements containing these nutrients. In most cases, mentally ill persons cannot become well using a special diet or indiscriminately stuffing themselves with amino acids, vitamins and minerals.
“The challenge is to carefully identify the specific nutrient overloads and deficiencies possessed by an individual and to provide treatments that normalise blood and brain levels of these chemicals with rifle-shot precision. This is the essence of biochemical therapy.” (Nutrient Power: Heal your biochemistry and heal your brain”, William Walsh, PhD)
At Evergreen Doctors we treat most mental health issues. We use a Functional Medicine approach and a holistic nutrient therapy program. These complement your medication and we work with you and your psychiatrist. Ultimately many patients can reduce or cease their medication entirely.
After a full history and examination, we perform specific testing to find any imbalance and then develop a program to correct it using specific nutrient therapy. This restores proper neurotransmission and is precise and personalised for each individual.
Some people are genetically predisposed to develop an imbalance, and although we can’t change your genetics, we can alter the epigenetic effects by changing your cellular environment. When we use specific nutrients for this, we don’t get the side effects arising from many drugs.
Nutrients can be powerful when used appropriately
Enhancement of antidepressant action of fluoxetine by folic acid: a randomised placebo control trial. Journal of Affective Disorders, Nov 2000, pp121—130
Treatment of depression: time to consider folic acid and B12.
Journal of Psychopharmacology, Jan 1 2005
“There is now evidence of a common decrease in folic acid and B12, an increase homocysteine and polymorphism of MTHFR C677T being overrepresented in depressive patients”
Enhancement of recovery from mental illness with L-methylfolate supplementation. Perspective Psychiatric Care: 2018 April 54, pp331—334
Folate in unipolar depressive illness, a systematic review and meta-analysis. J Psychopharmacology: 2018. April:32  pp377--384
Pyridoxine and the premenstrual syndrome: a randomised crossover trial. British Journal of General Practice. 1989: 39 364—368
Conclusion: There was a statistically significant benefit in depression, irritability and tiredness in the treated group.
Anti-depressive effect of pyridoxine in neuroleptic treated schizophrenic patients with co-morbid depression Harefuah [Israel] May 2001: 140 ; 369—373.
Conclusion: A subgroup of schizophrenic patients with co-morbid depression may benefit from pyridoxine added to their anti-psychotic treatment
B Complex Vitamin Patterns in Geriatric and Young Adult In patients with Major Depression. Journal of American Geriatrics Society: March 1991: Vol 39 issue 3
Conclusion: A poorer status of B Vitamins is present in major depression.
Zinc in CNS: From Molecules to Behaviour. “Biofactors” 2012 Mar 31
Covered role of zinc in transcription factors, gene regulation, transporters, neurogenesis, neurotransmission, AD, Depression, Stroke, Epilepsy. This paper alone had 81 references
Zinc supplementation in Major Depression: A RCT. Iran J Psychiatry. 2013 June 8, 73—79
SSRI plus zinc is more effective than SSRI plus placebo in treating depression. This paper alone had 26 reference articles
Zinc in Depression, A Meta-Analysis: Biological Psychiatry: 2013, Dec15, pp872—878
Considered 17 studies in 1643 patients. Concluded:
- Zinc concentrations 1.85micm/l lower in depressed patients.
- The lower the zinc concentration the more severe the depression.
- Low zinc levels are a marker of treatment resistant depression.
Association between magnesium intake and depression: Australian & New Zealand Journal of Psychiatry: Volume 43, 2009
5708 patients. “There is an inverse statistically significant association between dietary magnesium intake and depression score”
Magnesium and depression: A Systematic Review. Nutritional Neuroscience, Vol 16, 2013.
21 cross sectional studies, 3 interventional studies, one prospective trial. “A higher dietary intake of magnesium is associated with lower depression symptoms.”
 Pfeiffer CC , Brauermann ER: Zinc, the brain and behaviour. Biological Psychiatry, 1982; 4: 513-532.
 Osmond H & Hoffer A: Massive niacin treatment in schizophrenia. Review of a 9 year study, The Lancet 1963;1: 316-320.
 Hoffer A. Orthomolecular medicine for Physicians. New Canaan, CT, Keats Publ. 1978
 Simons L et al: Persistence with antihypertensive medication: Australia-wide experience. Medical Journal of Australia, 2008; 188: 224-227
 Walsh,W: Nutrients Help Alleviate Mental Illness. Well Being Journal, 2002; 11:
 McGinnis, W: Pyroluria: Hidden Cause of Schizophrenia, Bipolar, Depression, and Anxiety Symptoms. International Guide to the World of Alternative Mental Health. Orlando 21 May 2004.
 Hoffer, A.H. “The Discovery of Kryptopyrrole and its importance in diagnosis of Biochemical Imbalances in Schizophrenia and in Criminal Behaviour”, Journal of Orthomolecular Medicine, Vol 10, No.1, 1995.
 Pfeiffer C, LaMola B: Zinc and Manganese in Schizophrenia. The Journal of Orthomolecular Medicine, 1999;14: 28-48.
 Nowak G et al.:Zinc and Depression. An update. Pharmacol Rep, 2005; 57: 13-18.
 James, SJ et.al: Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. American Journal of Clinical Nutrition, 2004; 80: 1611-1617,
 Connor C and Akbarian S: DNA methylation changes in schizophrenia and bipolar disorder. Journal of the Epigenetics Society, 2008; 3:55-58,.
 Bottiglieri, T et al: Homocysteine, folate, methylation and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry, 2000; 69: 228-232.
 Kuratomi, G et al: Aberrant DNA methylation associated with bipolar disorder identified from discordant monozygotic twins. Molecular Psychiatry, 2008; 13: 429-441.
 Deth,R et al: How environmental and genetic factors cause autism. A redox/methylation hypothesis. Neurotoxicology, 2008; 1: 190-201.
 Walsh W et al: Reduced violence behavior following biochemical therapy. Physiol Behav. 2004; 82: 835-839.
 Regland B et al: Homocysteinaemia and schizophrenia as a case of methylation deficiency. Journal of Neural Transmission, 1994; 98: 143-152
 Maes M, D’Haese PC, Scharpe S et al: Hypozincaemia in Depression, J Affect Disord 1994; 31: 135-140.
 Maes M, Vandoolaeghe E, Neels H, et al: Lower zinc in major depression is a sensitive marker of treatment resistance and of immune/inflammatory response in that illness. Biol Psychiatry 1997;42:349-358,
 Akhondzadeh S et al: Zinc sulphate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: A double blind and randomized trial. BMC Psychiatry 2004; 4: 9.
 Takeda A et al: Anxiety like behaviour of young rats after 2 week’s zinc deprivation. Behavior Brain Research, 2007; 177: 1-6, .
 Yorbik O et al: Zinc Status in Autistic Children. The Journal of Trace Elements in Experimental Medicine, 2004; 17: 101- 107.
 Richard Stuckey, MB.BS., DRCOG; William Walsh, PhD; Brett Lambert, The Effectiveness of Targeted Nutrient Therapy in Treatment of Mental Illness, a pilot study, ACNEM Journal Vol 29 No 3 – November 2010, ACNEM Journal Vol 29 No 3 – November 2010
 Nutrients. 2018 Jan 30;10(2). pii: E152. doi: 10.3390/nu10020152. Database Analysis of Depression and Anxiety in a Community Sample-Response to a Micronutrient Intervention. Kimball SM, Mirhosseini N, Rucklidge J
 Acta Neuropsychiatr. 2015 Jun;27(3):168-76. doi: 10.1017/neu.2015.7. Dietary magnesium deficiency alters gut microbiota and leads to depressive-like behaviour. Winther G, Pyndt Jørgensen BM, Elfving B, Nielsen DS, Kihl P, Lund S, Sørensen DB, Wegener G